Bayer exceeds expectations - | the details:
Bayer surpasses market expectations.
deraktionaer.de/artikel/pharma-biotech/bayer-toppt-die-erwartungen-die-details-20405988.html
Story Details
| Last Updated | |
| Total Articles | 2 |
Main Topics
yearly report on a company or other organization's activities; publication type
News on this topic
Bayer: Tomorrow is the day!: Bayer will present its quarterly figures on August 4. Analysts expect a decline in sales and pressure on margins.
deraktionaer.de/artikel/pharma-biotech/bayer-morgen-zaehlt-es-20405994.html
Similar to This
Previous
Bayer stock continues to accelerate: This is what analysts are now advising: The pharmaceutical business is driving growth.
deraktionaer.de/artikel/pharma-biotech/bayer-aktie-gibt-weiter-gas-das-raten-jetzt-die-analysten-20434432.html
Bayer: One billion euros per quarter! Endless growth for this blockbuster: The pharmaceutical division has recently developed surprisingly strongly.
deraktionaer.de/artikel/pharma-biotech/bayer-eine-milliarde-euro-im-quartal-wachstum-ohne-ende-bei-diesem-blockbuster-20432063.html
Paid articlePaywall
Stock market news this evening: Dax and Dow fall on election day, oil prices rise after US attacks
manager-magazin.de/finanzen/boerse/dax-vor-den-midterm-wahlen-schwaecher-a-2357928a-aaa4-4d3f-abb5-164a89aec8e6
Bayer sees the "turning point" reached: New drugs are not only bringing high sales to the DAX-listed company, but are also highly profitable ...
faz.net/aktuell/wirtschaft/unternehmen/bayer-sieht-den-wendepunkt-erreicht-201646732.html
DAX Forecast: Lower - | US Midterms, Bayer, Lufthansa, FMC, BioNTech, AMD, Apple, Palantir in Focus
deraktionaer.de/artikel/indizes/dax-prognose-tiefer-us-midterms-bayer-lufthansa-fmc-biontech-amd-apple-palantir-im-fokus-20431435.html
Bayer delivers strong figures - | but a Monsanto legacy issue could prove costly: Bayer's quarterly results exceed expectations. However, CEO Bill Anderson ...
businessinsider.de/wirtschaft/bayer-liefert-starke-zahlen-doch-eine-monsanto-altlast-koennte-teuer-werden/
Paid articlePaywall
Bayer wins Roundup cancer trial after Supreme Court ruling: The weedkiller Roundup has been accused of being carcinogenic to humans despite no warning on its ...
dw.com/en/bayer-wins-roundup-cancer-trial-after-supreme-court-ruling/a-79803301
Court victory: Bayer's chances for glyphosate settlement increase: US judges in Missouri have once again ruled in favor of Bayer in a glyphosate trial ...
manager-magazin.de/unternehmen/pharma/bayer-gewinnt-ersten-glyphosat-prozess-a-cfdc1fd9-d137-45b1-83d4-bc42e853be30
Bayer stock: Price jump to the top of the DAX - | what the analysts are saying now
deraktionaer.de/artikel/pharma-biotech/bayer-aktie-kurssprung-an-die-dax-spitze-das-sagen-jetzt-die-analysten-20429517.html
Bayer stock falls and falls: Upward trend in danger: Bayer stock falls to a new multi-month low.
deraktionaer.de/artikel/pharma-biotech/bayer-aktie-faellt-und-faellt-aufwaertstrend-in-gefahr-20412747.html
Bayer: Historic success: Bayer receives FDA approval for Kerendia in chronic kidney disease and type 1 diabetes.
deraktionaer.de/artikel/pharma-biotech/bayer-historischer-erfolg-20408999.html
Bayer rival before mega IPO?: Syngenta is planning a $5 billion IPO in Hong Kong to position itself as a leading supplier in the agricultural sector.
deraktionaer.de/artikel/pharma-biotech/bayer-rivale-vor-mega-ipo-20408799.html
Bayer: Monsanto acquisition costs over 24 billion euros for plaintiffs and lawyers
handelsblatt.com/unternehmen/industrie/bayer-monsanto-kauf-kostet-ueber-24-milliarden-euro-fuer-klaeger-und-anwaelte/100216753.html
Bayer: Shares upgraded - | important decision expected by the end of June: Bayer kämpft an der 40-Euro-Marke. Die DZ Bank hat die Aktie auf "Halten" ...
deraktionaer.de/artikel/pharma-biotech/bayer-aktie-hochgestuft-wichtige-entscheidung-bis-ende-juni-erwartet-20398822.html
Bayer slips deep into the red due to glyphosate lawsuits: The glyphosate lawsuits in the US continue to weigh heavily on Bayer. The company is significantly ...
zdfheute.de/wirtschaft/unternehmen/bayer-milliardenverlust-glyphosat-rechtsstreit-100.html
Patents: Corona vaccines - | Bayer sues BioNTech, Pfizer and Moderna: Bayer accuses several manufacturers of copying an old technology to produce mRNA vaccines ...
handelsblatt.com/unternehmen/industrie/patente-corona-impfstoffe-bayer-verklagt-biontech-pfizer-und-moderna/100189227.html
This is how exposed European Big Pharma is to the U.S.: U.S. pricing has been the bigegts issue of the year for drugmakers heavily exposed to the U.S. market.
cnbc.com/2025/12/19/this-is-how-exposed-european-big-pharma-is-to-the-us.html
This is how exposed European Big Pharma is to the U.S.: U.S. pricing has been the bigegts issue of the year for drugmakers heavily exposed to the U.S. market.
cnbc.com/2025/12/19/this-is-how-exposed-european-big-pharma-is-to-the-us.html
Key FactsEuropean Pharma Faces Pressure from U.S. Market Rules
Dec 19, 2025 · Reading time: ~30 sec.
Summary created with AI assistance · Source: cnbc.com
Summary created with AI assistance · Source: cnbc.com
- The U.S. remains the dominant market for many European pharmaceutical companies, with some deriving up to 85% of sales there.
- President Trump’s Most Favored Nations pricing policy aims to lower drug costs in the U.S., potentially reducing pharma companies’ profit margins.
- Major players including AstraZeneca, Novo Nordisk, Roche, and Novartis are increasing investments and negotiating deals to comply with U.S. pricing demands.
- Concerns exist that these pricing measures and production shifts to the U.S. might limit drug availability in Europe and add operational challenges.
Bayer: Asundexian impresses in study and becomes a beacon of hope: In a new stroke study, Bayer is impressing with a drug that caused the company a significant ...
faz.net/aktuell/wirtschaft/unternehmen/bayer-asundexian-ueberzeugt-in-studie-und-wird-hoffnungstraeger-110790576.html
Bayer must set aside billions for glyphosate lawsuits – Deutsches Ärzteblatt
aerzteblatt.de/news/bayer-muss-milliarde-fur-glyphosat-klagen-zurucklegen-20d85c22-4f99-43df-bfa8-236196c9fc82
Next